Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 479703, 9 pages
http://dx.doi.org/10.1155/2015/479703
Review Article

Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis

Laboratoire d’Immunovirologie, Institut National de la Recherche Scientifique, INRS-Institut Armand-Frappier, Laval, QC, Canada H7V 1B7

Received 22 March 2015; Accepted 21 May 2015

Academic Editor: Stuart Berzins

Copyright © 2015 Pascal Lapierre and Alain Lamarre. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Y. Calne, R. A. Sells, J. R. Pena et al., “Induction of immunological tolerance by porcine liver allografts,” Nature, vol. 223, no. 5205, pp. 472–476, 1969. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Yang, Q. Liu, J. L. Grosfeld, and M. D. Pescovitz, “Intestinal venous drainage through the liver is a prerequisite for oral tolerance induction,” Journal of Pediatric Surgery, vol. 29, no. 8, pp. 1145–1148, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. L. E. Holz, V. Benseler, M. Vo et al., “Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a ‘neglected’ IL-2low Bimhigh phenotype, poor CTL function and cell death,” Journal of Hepatology, vol. 57, no. 4, pp. 830–836, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Sakaguchi, M. Miyara, C. M. Costantino, and D. A. Hafler, “FOXP3+ regulatory T cells in the human immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 490–500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. W. Virgin, E. J. Wherry, and R. Ahmed, “Redefining chronic viral infection,” Cell, vol. 138, no. 1, pp. 30–50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Ebinuma, N. Nakamoto, Y. Li et al., “Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection,” Journal of Virology, vol. 82, no. 10, pp. 5043–5053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Lüth, S. Huber, C. Schramm et al., “Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs,” The Journal of Clinical Investigation, vol. 118, no. 10, pp. 3403–3410, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Carambia, B. Freund, D. Schwinge et al., “Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice,” Journal of Hepatology, vol. 62, no. 6, pp. 1349–1356, 2015. View at Publisher · View at Google Scholar
  10. A. Carambia, B. Freund, D. Schwinge et al., “TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells,” Journal of Hepatology, vol. 61, no. 3, pp. 594–599, 2014. View at Publisher · View at Google Scholar
  11. P. J. Johnson and I. G. Mcfarlane, “Meeting report: international autoimmune hepatitis group,” Hepatology, vol. 18, no. 4, pp. 998–1005, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Alvarez, “Autoimmune hepatitis,” in Liver Disease in Childhood, F. Suchy, R. Sokol, and W. Baliestreri, Eds., Lippincott Williams & Wilkins, 2001. View at Google Scholar
  13. E. L. Krawitt, “Autoimmune hepatitis,” The New England Journal of Medicine, vol. 354, no. 1, pp. 54–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Béland, P. Lapierre, and F. Alvarez, “Influence of genes, sex, age and environment on the onset of autoimmune hepatitis,” World Journal of Gastroenterology, vol. 15, no. 9, pp. 1025–1034, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. C. Homberg, N. Abuaf, O. Bernard et al., “Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of ‘autoimmune’ hepatitis,” Hepatology, vol. 7, no. 6, pp. 1333–1339, 1987. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Maggiore, O. Bernard, J.-C. Homberg et al., “Liver disease associated with anti-liver-kidney microsome antibody in children,” The Journal of Pediatrics, vol. 108, no. 3, pp. 399–404, 1986. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Maggiore, F. Veber, O. Bernard et al., “Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents,” Journal of Pediatric Gastroenterology and Nutrition, vol. 17, no. 4, pp. 376–381, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. G. V. Gregorio, B. Portmann, F. Reid et al., “Autoimmune hepatitis in childhood: a 20-year experience,” Hepatology, vol. 25, no. 3, pp. 541–547, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Djilali-Saiah, R. Renous, S. Caillat-Zucman, D. Debray, and F. Alvarez, “Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients,” Journal of Hepatology, vol. 40, no. 6, pp. 904–909, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Martini, N. Abuaf, F. Cavalli, V. Durand, C. Johanet, and J.-C. Homberg, “Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2,” Hepatology, vol. 8, no. 6, pp. 1662–1666, 1988. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Abuaf, C. Johanet, P. Chretien et al., “Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis,” Hepatology, vol. 16, no. 4, pp. 892–898, 1992. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Lapierre, O. Hajoui, J.-C. Homberg, and F. Alvarez, “Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis,” Gastroenterology, vol. 116, no. 3, pp. 643–649, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Gueguen, O. Boniface, O. Bernard, F. Clerc, T. Cartwright, and F. Alvarez, “Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody,” Journal of Autoimmunity, vol. 4, no. 4, pp. 607–615, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. A. M. Yamamoto, D. Cresteil, O. Boniface, F. F. Clerc, and F. Alvarez, “Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti liver-kidney microsome type-1 antibodies (LKM1),” European Journal of Immunology, vol. 23, no. 5, pp. 1105–1111, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. M. P. Manns, E. F. Johnson, K. J. Griffin, E. M. Tan, and K. F. Sullivan, “Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1,” The Journal of Clinical Investigation, vol. 83, no. 3, pp. 1066–1072, 1989. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Ma, D. P. Bogdanos, M. J. Hussain et al., “Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2,” Gastroenterology, vol. 130, no. 3, pp. 868–882, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. S. Longhi, M. J. Hussain, D. P. Bogdanos et al., “Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2,” Hepatology, vol. 46, no. 2, pp. 472–484, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Czaja, “Autoimmune hepatitis. Part A: pathogenesis,” Expert Review of Gastroenterology & Hepatology, vol. 1, no. 1, pp. 113–128, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Holdener, E. Hintermann, M. Bayer et al., “Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection,” Journal of Experimental Medicine, vol. 205, no. 6, pp. 1409–1422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Piché, K. Béland, P. Lapierre, B. Massie, and F. Alvarez, “Different sites of xenoantigen delivery lead to a virally induced late-onset hepatitis in mice through molecular mimicry,” Liver International, vol. 31, no. 9, pp. 1306–1314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Hardtke-Wolenski, K. Fischer, F. Noyan et al., “Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells,” Hepatology, vol. 58, no. 2, pp. 718–728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Marceau, R. Yang, P. Lapierre, K. Béland, and F. Alvarez, “Low-dose anti-CD3 antibody induces remission of active autoimmune hepatitis in xenoimmunized mice,” Liver International, vol. 35, no. 1, pp. 275–284, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Lapierre, K. Béland, R. Yang, and F. Alvarez, “Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance,” Hepatology, vol. 57, no. 1, pp. 217–227, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Lapierre, K. Béland, C. Martin, and F. Alvarez Jr., “Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis,” Hepatology, vol. 51, no. 5, pp. 1789–1798, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Lapierre, K. Béland, I. Djilali-Saiah, and F. Alvarez, “Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development,” Journal of Autoimmunity, vol. 26, no. 2, pp. 82–89, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Lapierre, I. Djilali-Saiah, S. Vitozzi, and F. Alvarez, “A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens,” Hepatology, vol. 39, no. 4, pp. 1066–1074, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Lapierre, K. Béland, and F. Alvarez, “Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis,” Translational Research, vol. 149, no. 3, pp. 107–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Muratori, M. Cataleta, P. Muratori, M. Lenzi, and F. B. Bianchi, “Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis,” Gut, vol. 42, no. 5, pp. 721–726, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Viglietta, C. Baecher-Allan, H. L. Weiner, and D. A. Hafler, “Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis,” Journal of Experimental Medicine, vol. 199, no. 7, pp. 971–979, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. J. C. Crispin, A. Martínez, and J. Alcocer-Varela, “Quantification of regulatory T cells in patients with systemic lupus erythematosus,” Journal of Autoimmunity, vol. 21, no. 3, pp. 273–276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. M. S. Longhi, Y. Ma, D. P. Bogdanos, P. Cheeseman, G. Mieli-Vergani, and D. Vergani, “Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver disease,” Journal of Hepatology, vol. 41, no. 1, pp. 31–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Peiseler, M. Sebode, B. Franke et al., “FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency,” Journal of Hepatology, vol. 57, no. 1, pp. 125–132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Wang, A. Ioan-Facsinay, E. I. H. van der Voort, T. W. J. Huizinga, and R. E. M. Toes, “Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells,” European Journal of Immunology, vol. 37, no. 1, pp. 129–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. C. R. Grant, R. Liberal, B. S. Holder et al., “Dysfunctional CD39POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis,” Hepatology, vol. 59, no. 3, pp. 1007–1015, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. J. M. Fletcher, R. Lonergan, L. Costelloe et al., “CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis,” Journal of Immunology, vol. 183, no. 11, pp. 7602–7610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. M. S. Longhi, Y. Ma, R. R. Mitry et al., “Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis,” Journal of Autoimmunity, vol. 25, no. 1, pp. 63–71, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. M. S. Longhi, M. J. Hussain, R. R. Mitry et al., “Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis,” The Journal of Immunology, vol. 176, no. 7, pp. 4484–4491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. M. S. Longhi, F. Meda, P. Wang et al., “Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis,” Hepatology, vol. 47, no. 2, pp. 581–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. S. Longhi, M. J. Hussain, W. W. Kwok, G. Mieli-Vergani, Y. Ma, and D. Vergani, “Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis,” Hepatology, vol. 53, no. 2, pp. 536–547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. J. M. Vierling, “Autoimmune hepatitis and antigen-specific T regulatory cells: when can we send in the regulators?” Hepatology, vol. 53, no. 2, pp. 385–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Liberal, C. R. Grant, B. S. Holder et al., “The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway,” Hepatology, vol. 56, no. 2, pp. 677–686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. H. Oo, C. J. Weston, P. F. Lalor et al., “Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver,” Journal of Immunology, vol. 184, no. 6, pp. 2886–2898, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. L. Li, N. Liu, D. T. Zhao et al., “Investigate circulating levels of chemokines and evaluate the correlation between these chemokines and liver function indicators in autoimmune hepatitis,” Chinese Journal of Hepatology, vol. 21, pp. 299–303, 2013. View at Google Scholar
  55. A. Erhardt, C. Wegscheid, B. Claass et al., “CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis,” The Journal of Immunology, vol. 186, no. 9, pp. 5284–5293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. M. S. Longhi, R. Liberal, B. Holder et al., “Inhibition of interleukin-17 promotes differentiation of CD25—cells into stable T regulatory cells in patients with autoimmune hepatitis,” Gastroenterology, vol. 142, no. 7, pp. 1526.e6–1535.e6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Tao, E. F. de Zoeten, E. Özkaynak et al., “Deacetylase inhibition promotes the generation and function of regulatory T cells,” Nature Medicine, vol. 13, no. 11, pp. 1299–1307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. U. Protzer, M. K. Maini, and P. A. Knolle, “Living in the liver: hepatic infections,” Nature Reviews Immunology, vol. 12, no. 3, pp. 201–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Thimme, D. Oldach, K.-M. Chang, C. Steiger, S. C. Ray, and F. V. Chisari, “Determinants of viral clearance and persistence during acute hepatitis C virus infection,” Journal of Experimental Medicine, vol. 194, no. 10, pp. 1395–1406, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. S.-H. Park, N. S. Veerapu, E.-C. Shin et al., “Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection,” Nature Medicine, vol. 19, no. 12, pp. 1638–1642, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Sturm, M.-A. Thélu, X. Camous et al., “Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis,” Journal of Hepatology, vol. 53, no. 1, pp. 25–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. P. T. Losikoff, A. A. Self, and S. H. Gregory, “Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C,” Virulence, vol. 3, no. 7, pp. 610–620, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. A. J. MacDonald, M. Duffy, M. T. Brady et al., “CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons,” Journal of Infectious Diseases, vol. 185, no. 6, pp. 720–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Cabrera, Z. Tu, Y. Xu et al., “An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection,” Hepatology, vol. 40, no. 5, pp. 1062–1071, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Sugimoto, F. Ikeda, J. Stadanlick, F. A. Nunes, H. J. Alter, and K.-M. Chang, “Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection,” Hepatology, vol. 38, no. 6, pp. 1437–1448, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. X. Zhou, S. Ramachandran, M. Mann, and D. L. Popkin, “Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future,” Viruses, vol. 4, no. 11, pp. 2650–2669, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Moskophidis, F. Lechner, H. Pircher, and R. M. Zinkernagel, “Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells,” Nature, vol. 362, no. 6422, pp. 758–761, 1993. View at Publisher · View at Google Scholar
  68. E. J. Wherry, “T cell exhaustion,” Nature Immunology, vol. 12, no. 6, pp. 492–499, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Penaloza-MacMaster, A. O. Kamphorst, A. Wieland et al., “Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection,” Journal of Experimental Medicine, vol. 211, no. 9, pp. 1905–1918, 2014. View at Publisher · View at Google Scholar
  70. P. Lapierre, V. Janelle, M. Langlois, E. Tarrab, T. Charpentier, and A. Lamarre, “Expression of viral antigen by the liver leads to chronic infection through the generation of regulatory T cells,” CMGH Cellular and Molecular Gastroenterology and Hepatology, vol. 1, no. 3, pp. 325.e1–341.e1, 2015. View at Publisher · View at Google Scholar
  71. B. T. Rouse and S. Suvas, “Regulatory cells and infectious agents: détentes cordiale and contraire,” Journal of Immunology, vol. 173, no. 4, pp. 2211–2215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. J. R. Teijaro, C. Ng, A. M. Lee et al., “Persistent LCMV infection is controlled by blockade of type I interferon signaling,” Science, vol. 340, no. 6129, pp. 207–211, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. E. B. Wilson, D. H. Yamada, H. Elsaesser et al., “Blockade of chronic type I interferon signaling to control persistent LCMV infection,” Science, vol. 340, no. 6129, pp. 202–207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Vincenti, R. Kirkman, S. Light et al., “Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation,” New England Journal of Medicine, vol. 338, no. 3, pp. 161–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. A. J. Rech and R. H. Vonderheide, “Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells,” Annals of the New York Academy of Sciences, vol. 1174, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. D. J. Huss, D. S. Mehta, A. Sharma et al., “In vivo maintenance of human regulatory T cells during CD25 blockade,” The Journal of Immunology, vol. 194, pp. 84–92, 2015. View at Google Scholar